Specific Activation of 2'-5'oligoadenylate Synthetase Gene Promoter by Hepatitis C Virus-core Protein: a Potential for Developing Hepatitis C Virus Targeting Gene Therapy

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2009 Jul 4

PMID 19575500

Authors

Ying Wang

Shan-Shan Mao

Qiong-Qiong He

Yuan Zi

Ji-Fang Wen

De-Yun Feng

Affiliations

Soon will be listed here.

Abstract

Aim: To examine whether 2'-5'oligoadenylate synthetase (OAS) gene promoter can be specifically activated by hepatitis C virus (HCV)-core protein.

Methods: Human embryo hepatic cell line L02 was transfected with pcDNA3.1-core plasmid and selected by G418. Expression of HCV-core was detected by reverse transcription polymerase chain reaction and Western blotting. The OAS promoter sequence was amplified from the genomic DNA and inserted into pGL3-basic vector. The resultant pGL3-OAS-Luci plasmid was transiently transfected into L02/core cells and luciferase activity was assayed.

Results: L02/core cell line stably expressing HCV-core protein was established. The pGL3-OAS-Luci construct exhibited significant transcriptional activity in the L02/core cells but not in the L02 cells.

Conclusion: HCV-core protein activates the OAS gene promoter specifically and effectively. Utilization of OAS gene promoter would be an ideal strategy for developing HCV-specific gene therapy.

References

Ji J, Glaser A, Wernli M, Berke J, Moradpour D, Erb P . Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. J Gen Virol. 2008; 89(Pt 11):2761-2766. DOI: 10.1099/vir.0.2008/002923-0. View

Major M, Feinstone S . The molecular virology of hepatitis C. Hepatology. 1997; 25(6):1527-38. DOI: 10.1002/hep.510250637. View

Ray R, Steele R, Meyer K, Ray R . Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem. 1997; 272(17):10983-6. DOI: 10.1074/jbc.272.17.10983. View

Weber F . Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol. 2007; 13(36):4818-23. PMC: 4611759. DOI: 10.3748/wjg.v13.i36.4818. View

Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. DOI: 10.1126/science.2523562. View

Bergqvist A, Rice C . Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J Virol. 2001; 75(2):772-81. PMC: 113973. DOI: 10.1128/JVI.75.2.772-781.2001. View

Kato N, Yoshida H, Ono-Nita S, Kato J, Goto T, Otsuka M . Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. 2000; 32(2):405-12. DOI: 10.1053/jhep.2000.9198. View

Gonzalez-Aseguinolaza G, Crettaz J, Ochoa L, Otano I, Aldabe R, Paneda A . Gene therapy for viral hepatitis. Expert Opin Biol Ther. 2007; 6(12):1263-78. DOI: 10.1517/14712598.6.12.1263. View

Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K . Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology. 1999; 258(1):100-7. DOI: 10.1006/viro.1999.9694. View

10.

Basu A, Meyer K, Ray R, Ray R . Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology. 2001; 288(2):379-90. DOI: 10.1006/viro.2001.1100. View

11.

Lee M, Jung E, Kwun H, Jun H, Yu D, Choi Y . Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J Gen Virol. 2002; 83(Pt 9):2145-2151. DOI: 10.1099/0022-1317-83-9-2145. View

12.

de Lucas S, Bartolome J, Carreno V . Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis. 2004; 191(1):93-9. DOI: 10.1086/426509. View

13.

Galanis E, Vile R, Russell S . Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001; 38(3):177-92. DOI: 10.1016/s1040-8428(01)00103-2. View

14.

Robson T, Hirst D . Transcriptional Targeting in Cancer Gene Therapy. J Biomed Biotechnol. 2003; 2003(2):110-137. PMC: 323956. DOI: 10.1155/S1110724303209074. View

15.

Hoofnagle J . Hepatitis C: the clinical spectrum of disease. Hepatology. 1997; 26(3 Suppl 1):15S-20S. DOI: 10.1002/hep.510260703. View

16.

Shrivastava A, Manna S, Ray R, Aggarwal B . Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J Virol. 1998; 72(12):9722-8. PMC: 110482. DOI: 10.1128/JVI.72.12.9722-9728.1998. View

17.

Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M . Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol. 2000; 74(18):8744-50. PMC: 116387. DOI: 10.1128/jvi.74.18.8744-8750.2000. View

18.

Ray R, Lagging L, Meyer K, Steele R, Ray R . Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res. 1995; 37(3):209-20. DOI: 10.1016/0168-1702(95)00034-n. View